Email this article 
Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study - PDF (Russian)
Copyright (c) 2022 Nesterova E.S., Saydullaeva A.F., Sherstnev D.G., Shelekhova T.V., Klitochenko T.Y., Khusainova G.N., Lysenko I.B., Lyalina I.S., Demchenkova M.V., Orlova S.A., Proydakov A.V., Betrozova M.V., Fadeeva N.V., Gofman A.A., Marchenko Y.M., Voloshin S.V., Pashneva E.A., Sarzhevskiy V.O., Ishchanov D.G., Poddubnaya I.V.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.